CTI BioPharma Corp.’s stock is up ten-fold this week after the Food and Drug Administration lifted a year-long clinical suspension and the company executed a reverse stock split.
CTI’s share price has increased about 22 percent since Thursday, when it was announced that the FDA lifted a hold on myelofibrosis drug trials using the Seattle-based biotech company’s lead pipeline drug pacritinib.
That surge came on the heels of a reverse stock split Jan. 1 that buoyed share price from 39 cents…
CTI BioPharma Corp.’s stock is up ten-fold this week after the Food and Drug Administration lifted a year-long clinical suspension and the company executed a reverse stock split.
CTI’s share price has increased about 22 percent since Thursday, when it was announced that the FDA lifted a hold on myelofibrosis drug trials using the Seattle-based biotech company’s lead pipeline drug pacritinib.
That surge came on the heels of a reverse stock split Jan. 1 that buoyed share price from 39 cents…